Stock comparison
Halozyme Therapeutics
Novo Nordisk A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
NVO
Novo Nordisk A/S
Market cap
$199.21B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | NVO | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 65B | HALO |
| Benjamin Graham | 83A | 61C | HALO |
| Philip Fisher | 65B | 73B | NVO |
| Peter Lynch | 53D | 57C | NVO |
| Joel Greenblatt | 40D | 56C | NVO |
| Charlie Munger | 80C | 76B | HALO |
| Terry Smith | 84A | 72C | HALO |
Side-by-side metrics
| Metric | HALO | NVO |
|---|---|---|
| Market cap | $8.1B | $199.21B |
| P/E (TTM) | 24.0x | 10.4x |
| EV/EBIT | 10.2x | 10.9x |
| ROIC (TTM) | 23.65% | 32.2% |
| Gross margin | 81.24% | 81.85% |
| Net margin | 23.13% | 37.2% |
| Revenue CAGR 5y | 33.23% | 21.72% |
| EPS CAGR 5y | -1.98% | 22.03% |
| Debt / Equity | 1.0x | 0.7x |
| Dividend yield | 0.0% | 4.09% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 21.72%+35%
- EV/EBIT10.2xvs 10.9x+7%
NVO leads on
- EPS CAGR 5y22.03%vs -1.98%+109%
- Dividend yield4.09%vs 0.0%+100%
- Market cap$199.21Bvs $8.1B+96%
- P/E (TTM)10.4xvs 24.0x+57%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.